Pharmacodynamics<unk>  is a nonsteroidal antiandrogen, acting specifically as an androgen synthesis inhibitor via inhibition of the enzyme CYP17A1, for the treatment of castration-resistant prostate cancer. It has approximately 10-fold selectivity for the inhibition of 17,20-lyase ( = 69 nM) over 17α-hydroxylase ( = 670 nM), which results in less interference with corticosteroid production relative to the approved CYP17A1 inhibitor abiraterone acetate (which must be administered in combination with prednisone to avoid glucocorticoid deficiency and mineralocorticoid excess due to 17α-hydroxylase inhibition) and hence may be administerable without a concomitant exogenous glucocorticoid.<unk>  is 58-fold more selective for inhibition of 17,20-lyase than abiraterone (the active metabolite of abiraterone acetate), which has values for inhibition of 17,20-lyase and 17α-hydroxylase of 15 nM and 2.5 nM, respectively. In addition, in in vitro models,<unk>  appears to possess greater efficacy as an antiandrogen relative to abiraterone. Similarly to abiraterone acetate,<unk>  has also been found to act to some extent as an antagonist of the androgen receptor.
Seviteronel
Vibegron
Clinatec
Telotristat ethyl
Crofelemer
Titermax
Palifermin
Tebentafusp